WO2015183041A1 - 포도상구균 감염 질환의 예방 또는 치료용 조성물 - Google Patents
포도상구균 감염 질환의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2015183041A1 WO2015183041A1 PCT/KR2015/005431 KR2015005431W WO2015183041A1 WO 2015183041 A1 WO2015183041 A1 WO 2015183041A1 KR 2015005431 W KR2015005431 W KR 2015005431W WO 2015183041 A1 WO2015183041 A1 WO 2015183041A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wta
- pgn
- cells
- infection
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 206010041925 Staphylococcal infections Diseases 0.000 title claims abstract description 24
- 208000015339 staphylococcus aureus infection Diseases 0.000 title abstract 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims abstract description 92
- 108010013639 Peptidoglycan Proteins 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 49
- 208000015181 infectious disease Diseases 0.000 claims abstract description 40
- 206010057249 Phagocytosis Diseases 0.000 claims abstract description 10
- 230000008782 phagocytosis Effects 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 30
- 229940088598 enzyme Drugs 0.000 claims description 30
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 19
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000004357 Transferases Human genes 0.000 claims description 16
- 108090000992 Transferases Proteins 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 12
- MNLRQHMNZILYPY-MKFCKLDKSA-N N-acetyl-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MKFCKLDKSA-N 0.000 claims description 12
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 12
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 11
- 108010014251 Muramidase Proteins 0.000 claims description 10
- 102000016943 Muramidase Human genes 0.000 claims description 10
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 10
- 239000004325 lysozyme Substances 0.000 claims description 10
- 229960000274 lysozyme Drugs 0.000 claims description 10
- 235000010335 lysozyme Nutrition 0.000 claims description 10
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 9
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 claims description 9
- 229960003085 meticillin Drugs 0.000 claims description 9
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 claims description 8
- 101150020801 oatA gene Proteins 0.000 claims description 8
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 claims description 7
- 241000191940 Staphylococcus Species 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 230000031261 interleukin-10 production Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 108010009719 mutanolysin Proteins 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 2
- 208000031729 Bacteremia Diseases 0.000 claims description 2
- 206010016952 Food poisoning Diseases 0.000 claims description 2
- 208000019331 Foodborne disease Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 208000031650 Surgical Wound Infection Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 206010036410 Postoperative wound infection Diseases 0.000 claims 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims 1
- 244000250129 Trigonella foenum graecum Species 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 28
- 238000006243 chemical reaction Methods 0.000 abstract description 14
- 230000001404 mediated effect Effects 0.000 abstract description 9
- 210000000440 neutrophil Anatomy 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000006044 T cell activation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 92
- 108050003558 Interleukin-17 Proteins 0.000 description 82
- 102000013691 Interleukin-17 Human genes 0.000 description 82
- 241000699670 Mus sp. Species 0.000 description 69
- 230000014509 gene expression Effects 0.000 description 60
- 239000002953 phosphate buffered saline Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 39
- 230000003053 immunization Effects 0.000 description 33
- 206010000269 abscess Diseases 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 238000002649 immunization Methods 0.000 description 30
- 238000002347 injection Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 210000004443 dendritic cell Anatomy 0.000 description 24
- 230000002950 deficient Effects 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 18
- 210000000683 abdominal cavity Anatomy 0.000 description 18
- 238000010828 elution Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 230000001681 protective effect Effects 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 15
- 230000005651 interleukin-17A production Effects 0.000 description 15
- 239000008188 pellet Substances 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000008215 water for injection Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 101150061038 NLRP3 gene Proteins 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 108090001030 Lipoproteins Proteins 0.000 description 9
- 102000004895 Lipoproteins Human genes 0.000 description 9
- 239000012506 Sephacryl® Substances 0.000 description 9
- 241000295644 Staphylococcaceae Species 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 101150010952 OAT gene Proteins 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000012224 gene deletion Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 5
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 5
- 208000035415 Reinfection Diseases 0.000 description 5
- 206010040893 Skin necrosis Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001641 gel filtration chromatography Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 229910001961 silver nitrate Inorganic materials 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 3
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 3
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 3
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 3
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 2
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010034649 Peritoneal abscess Diseases 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101100368828 Staphylococcus aureus (strain COL) tarM gene Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000000540 fraction c Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920000550 glycopolymer Polymers 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000003704 interleukin-23 production Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 101150094979 lgt gene Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000011269 tar Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229960004175 xylazine hydrochloride Drugs 0.000 description 2
- YGOAYNVRTAEAAI-GKZUZGRISA-N (2R)-2-[(3R,4R,5S,6R)-2-acetyl-3-amino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoic acid Chemical compound C(C)(=O)C1(O)[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YGOAYNVRTAEAAI-GKZUZGRISA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- ZUQUTHURQVDNKF-WZPXOXCRSA-N 1-[(3S,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical compound C(C)(=O)C1(O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO ZUQUTHURQVDNKF-WZPXOXCRSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- DGPBVJWCIDNDPN-UHFFFAOYSA-N 2-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=CC=C1C=O DGPBVJWCIDNDPN-UHFFFAOYSA-N 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710102974 O-acetyl transferase Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101150038509 TLR9 gene Proteins 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 241000254109 Tenebrio molitor Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- DHNCFAWJNPJGHS-UHFFFAOYSA-J [C+4].[O-]C([O-])=O.[O-]C([O-])=O Chemical compound [C+4].[O-]C([O-])=O.[O-]C([O-])=O DHNCFAWJNPJGHS-UHFFFAOYSA-J 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical group OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003246 kidney medulla Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- XRRQZKOZJFDXON-UHFFFAOYSA-N nitric acid;silver Chemical compound [Ag].O[N+]([O-])=O XRRQZKOZJFDXON-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108010069727 pro-phenoloxidase Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
Definitions
- compositions for the Prevention or Treatment of Staphylococcal Infectious Diseases Field of the Invention relate to a composition for the prevention or treatment of Staphylococcal infection diseases, and more particularly, to D. teicosan-attached peptidoglycan (WTA-PGN).
- WTA-PGN D. teicosan-attached peptidoglycan
- a composition comprising as an active ingredient, a method for preventing or treating staphylococcal infection disease using the composition, and a method for producing a soluble WTA-PGN that can be used as an active ingredient in the composition.
- St aphyl ococcus aureus can cause severe infections in human skin, soft tissues and bloodstream (Lowy FD, The New England journal of medicine, 339: 520—532, 1998).
- Staphylococcus aureus can be transformed into a methicillin-resistant strain (MRSA) that is resistant to beta-lactam antibiotic methicillin for various reasons. Difficult to treat and poor prognosis has become a major social problem.
- MRSA methicillin-resistant strain
- CA-MRSA co-unity-associated MRSAs
- H-MRSA conventional hospital-associated strains
- USA300 MRSA strains are spreading in the United States causing serious diseases in children or people with reduced immune function, it is required to develop a new vaccine or treatment that has a prophylactic and therapeutic effect against MRSA infection.
- researchers who tried to develop staphylococcal vaccine candidates had a good prognosis in clinical trials. Because of the failure, staphylococcal vaccines that have been clinically useful until recently have not been developed.
- T cell-mediated IL-17A is required to generate both neutrophil recruitment and cellular i ⁇ unity to promote phagocytosis, and phagocytic cell effector by T cell activation. It has been suggested that it can play a protective role against staphylococcal infections by promoting the function. In addition, studies have shown that staphylococcal infections have a protective effect against infection by increasing the number of memory ⁇ ⁇ - ⁇ cells in mouse models (J. Immunol., 192 (8): 3697-). 708, 2014).
- ligand material of bacteria recognized by biodefense proteins is not clearly identified, it is difficult to treat and prevent infectious diseases caused by pathogens.
- ligands such as cell wall components of staphylococci, ⁇ , LTA, PGN, CP, and lipoproteins, are mainly glycopolymers, and their structure is very complicated and purified together with other substances. Difficult to do
- various cell wall components are exposed to the outside, it is difficult to identify which component acts as a ligand of the host's biological defense protein.
- WTA-PGN WTA-attached PGN
- WTA-PGN WTA-attached PGN
- Another object of the present invention to provide a method for preventing or treating staphylococcal infection disease using the composition.
- the present invention provides a composition for the prevention or treatment of staphylococcal infection disease, including peptidoglycan (WTA-PGN) attached to the wall teicosane.
- WTA-PGN peptidoglycan
- the present invention provides a method for preventing or treating Staphylococcal infection disease, comprising administering the above-described composition to a subject.
- the present invention comprises the steps of (1) obtaining a double mutant strain deleted / ⁇ (l ipoprotein di acylglycerol transferase) and oatAiO-acetyl transferase) gene from wild type staphylococci; (2) disrupting said double mutant strain and obtaining insoluble WTA-PGN from the resulting lysate; (3) treating the insoluble WTA-PGN with ⁇ -lyt ic enzyme; (4) obtaining a soluble WTA-PGN containing fraction from the enzyme treatment of step (3); (5) treating the soluble WTA-PGN containing fractions with lysozyme or mutanolysine; And (6) obtaining soluble WTA-PGN from the enzymatic treatment of step (5), providing a method for preparing soluble
- Figure 4 shows the result of quantifying the elution pattern (A), gel mobility (B), and the amount of IL-17A produced when injected into the mouse intraperitoneally separated WTA-PGN by Sephacryl S-200 HR column (C).
- FIG. 5 shows the elution pattern 5A separating the WTA-PGN with the first C18 reversed phase column, gel mobility 5B, the elution pattern 5C separated with the second C18 reversed phase column, gel mobility 5D and FIG. 5A.
- the quantification results (5E) of the amount of IL-7A induced by mouse injection of A, B, C,! And E fractions are shown.
- Figure 6 shows the elution pattern (A) and gel mobility (B) separated by HiTrap-Q column after TCA treatment to insoluble WTA PGN.
- Figure 7 shows the elution pattern of soluble PGN separated by Hitrap-Q column.
- Figure 8 shows the elution pattern of soluble PGN separated in a Toyopearl HW 55 S column.
- FIG. 9 shows 27% PAGE and silver nitrate staining (A), silica gel thin layer chromatography (B) and amounts of phosphate and GlcNAc residues (C) for WTA-PGN and WTA.
- FIG. 10 shows time schedules for three-time immunization of WTA, PGN and WTA-PGN intraperitoneally and MRSA JSA300) infections to observe ⁇ cell induced early cellular and memory immunity.
- FIG. 11 shows the production of IL-17A (11A) and IL-1] 3 (11B) by intraperitoneal administration to mice of PBS, WTA-PGN and a combination of WTA and PGN at various concentrations and times.
- Figure 13 shows the results of analysis of the distribution ratio of ⁇ ⁇ T cells producing IL-17A after injection of PBS and WTA-PGN using flow cytometry.
- FIG. 14 shows CD4 + and CD8 + T cell mediated IL-17A production following injection of PBS and WTA-PGN.
- FIG. 15 shows the production amount of IL-17A (15A) and the production amount of IL- ⁇ (15B) by PBS, WTA-PGN, and a combination of WTA and PGN in wild-type and VY 2/4 — / _ mice.
- Figure 16 shows IL-17A (16A), IL-1P (16B), IL-23 (16C), IFNy (16D) induced by infection of the USA300 strain in each mouse pretreated with PBS, WTA, PGN and WTA-PGN. ) And IL-10 16E).
- FIG. 17 Memory ⁇ ⁇ in ⁇ ⁇ T cells of mice pretreated with WTA-PGN Expression levels of CD44 and CD27, markers of T cells ( ⁇ 7 ⁇ ), and expression levels of IL-17A in these memory ⁇ ⁇ ⁇ cells (17B) are shown.
- Fig. 18 shows the IL-17A expression level in memory ⁇ ⁇ ⁇ cells in each mouse pretreated with PBS, WTA-PGN, PGN and ⁇ , and the intracellular IL-17A production amount by FACS (18A); (B) Extracellular IL-17A production amount (18B) by ELISA is shown.
- 21 shows IL-23 expression levels in dendritic cells in mice pretreated with WTA-PGN and mice not pretreated.
- FIG. 22 is a photograph showing the organ shape and abscess formation in the abdominal cavity of mice infected with USA300 strain after pretreatment with PBS, WTA, PGN and WTA—PGN.
- Figure 23 shows survival results for USA300 infection in mice immunized with WTA-PGN induced memory Y S ⁇ cells.
- FIG. 24 shows abscess morphology (24A) and abscess volume ( 24B) in mice infected with methicillin-sensitive staphylococcus (MSSA 5. aureus NRS184 strain) after immunization with WTA-PGN.
- MSSA methicillin-sensitive staphylococcus
- 25 shows whether skin abscess formation (25A), area of skin necrosis area (25B) and abscess volume (25C) in NZW rabbits infected with MRSA after WTA-PGN immunization . Quantification results are shown.
- FIG. 26 shows the results of quantification of skin abscess formation, area of skin necrosis area and abscess volume in NZW rabbits (A) and junior pigs (B) after WTA-PGN immunization.
- Figure 27 is a photograph observing the abscess and hemolysis in the abdominal cavity after infection with MRSA of the guinea pig immunized with WTA-PGN.
- Figure 28 shows the results of measuring the production of IL-17A (28A) and IL- ⁇ (28B) in wild-type, TLR-9-gene-deficient and Caspase-1-gene-deficient mice immunized with WTA-PGN.
- 29 shows expression levels of IL-17A (29A), IL- ⁇ (29B), IL-23C29C) and IFNy (29D) in macrophages, dendritic cells and ⁇ ⁇ T cells of mice obtained after pretreatment with WTA-PGN. Is the result of measuring.
- FIG. 30 shows gene expression patterns (30A-30J) induced upon WTA-PGN injection in wild type and NLRP3 gene deficient mice.
- FIG. 31 shows the time schedule of experiments in which MRSA USA 300 was infected with tail vein in each mouse immunized subcutaneously with WTA, PGN and WTA-PGN to observe humoral immune response by anti-IgG production. ⁇
- FIG. 33 shows the weight change of mice one week after USA300 cell infection in mice immunized with WTA, PGN and WTA-PGN.
- FIG. 34 shows kidney images and bacterial loads (CFUs) of mice immunized with WTA, PGN and WTA-PGN, showing (i) PBS, (ii) WTA and (iii) WTA—attached PGN.
- FIG. 35 shows histopathological images in mouse kidney after MRSA USA300) infection with bloodstream after immunization with ⁇ , PGN and WTA-PGN.
- wall teichoic acid refers to Staphylococcus aureus (5. As one of the cell wall components of glycerol phosphate repeat unit and ribi phosphate repeat unit (N-acetylmannosamine)-
- ept idoglycan refers to a repeat glycopolymer of N-acetylmuramate (MurNAc) and N-acetylglucosamine (GlcNAc) linked by stem-peptide linkages.
- wall teichoic acid (TA) -attached peptidoglycan (PGN) refers to a structure in which the wall teichoic acid and peptidoglycan are covalently bonded and interchanged with ⁇ -PGN 'herein. Used as an enemy.
- the present invention provides a composition for the prevention or treatment of Staphylococcal infection disease, which comprises a wall teichoic acid (WTA) -attached peptidoglycan (PGN) as an active ingredient.
- WTA wall teichoic acid
- PPN peptidoglycan
- the wall teichoic acid-attached peptidoglycan (WTA-PGN) may be represented by the following general formula (1).
- the wall teichoic acid-attached peptidoglycan may be represented by Formula 1, wherein n is an integer of 10 to 50; m is an integer from 1 to 3; A is N-acetylmannosamine (ManNAc); B is
- N ⁇ acetylglucosamine (GlcNAc); 0 and P are each independently an integer from 0 to 5; 3 ⁇ 4 to 3 ⁇ 4 are each independently hydroxy, tetrapeptide or pentapeptide; R 4 is hydroxy or N—acetylmuramic acid (MurNAc);
- the wall teichoic acid-attached peptidoglycan may be represented by Formula 1, wherein ⁇ is an integer from 35 to 45; m is 3; A is N-acetylmannosamine (ManNAc); B is N-acetylglucosamine (GlcNAc); 0 and P are each independently an integer from 0 to 3; 3 ⁇ 4 to R 3 are each independently hydroxy, tetrapeptide or meptamide; 3 ⁇ 4 is hydroxy or N-acetylmuramic acid (Mur NAc).
- ⁇ is an integer from 35 to 45; m is 3; A is N-acetylmannosamine (ManNAc); B is N-acetylglucosamine (GlcNAc); 0 and P are each independently an integer from 0 to 3; 3 ⁇ 4 to R 3 are each independently hydroxy, tetrapeptide or meptamide; 3 ⁇ 4 is hydroxy or N-acetylmuramic acid (Mur NAc).
- the wall teichoic acid-attached peptidoglycan may be represented by Formula 1, wherein n is 40; m is 3; A is N ⁇ acetylmannosamine (ManNAc); B is N-acetylglucosamine (GlcNAc);
- 0 and P are each independently an integer from 0 to 5; And 3 ⁇ 4 is tetrapeptide;
- R 3 is hydroxy, tetrapeptide or pentapeptide; Is hydroxy or
- the wall teichoic acid-attached peptidoglycan may be represented by Formula 1, wherein n is 40; m is 3; A is N-acetylmannosamine (ManNAc); B is N-acetylglucosamine (GlcNAc);
- Ri and 3 ⁇ 4 are tetrapeptides; Is hydroxy, tetrapeptide or pentapeptide;
- the tetrapeptide is -ArAa-As—A4, where is Ala or Gly, A 2 is Glu or Asp, A 3 is Lys, Arg or His, A 4 is Ala or Gly, and R4 is hydroxy or N-acetylmuramic acid (MurNAc).
- the wall teichoic acid-attached peptidoglycan may be represented by Formula 1, wherein n is 40; m is
- Ri and R 2 are tetrapeptides
- R 3 is hydroxy, tetrapeptide or pentapeptide; Said tetrapeptide is-(L-Ala)-(D-Glu)-(L-Lys)-(D-Ala); 3 ⁇ 4 is hydroxy or
- any one of 3 ⁇ 4 to 3 ⁇ 4 of the wall teichoic acid-attached peptidoglycan may form a crosslink with any one of 3 ⁇ 4 to 3 ⁇ 4 of the other FTA-PGN. Accordingly, the WTA-PGN may also exist in the form of a dimer in which two WTA-PGNs are combined.
- composition according to the present invention can be used for the prophylaxis or treatment of staphylococcal infection disease, the staphylococcus causing the staphylococcal infection disease is methicillin-resistant staphylococcus aureus (MRSA), methicillin -Method ⁇ -sensitive 5 «3 ⁇ 43 ⁇ 43 ⁇ 4 ⁇ / ⁇ : ⁇ 7 ⁇ 5 awre s (MSSA) or pathogenic staphylococci.
- MRSA methicillin-resistant staphylococcus aureus
- MSSA methicillin -Method ⁇ -sensitive 5 «3 ⁇ 43 ⁇ 43 ⁇ 4 ⁇ / ⁇ : ⁇ 7 ⁇ 5 awre s
- staphylococcal infections include soft tissue infections, purulent arthritis, purulent osteomyelitis, otitis media, pneumonia, sepsis, acute respiratory tract infection, infections caused by the use of catheters, postoperative wound infections, bacteremia, endocarditis or Food poisoning, but is not limited thereto.
- composition according to the present invention may further comprise a pharmaceutically acceptable carrier, diluent and / or adjuvant in addition to the WTA-PGN.
- Carriers used in the compositions according to the invention include methods and routes of administration, and Selected based on standard drug compositions, for example, carrier proteins (ie, bovine serum albumin (BSA), egg white albumin (OVA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH)), solubilizers ( Ethane, polysorbate and Cremophor EL TM, isotonic agents, preservatives, antioxidants, excipients (ie, lactose, starch, crystalline salose, manni, maltose, calcium hydrogen phosphate, light anhydrous silicic acid and Carbon carbonate), binders (i.e.
- carrier proteins ie, bovine serum albumin (BSA), egg white albumin (OVA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH)
- solubilizers Ethane, polysorbate and Cremophor EL TM, isotonic agents, preservative
- the vaccine composition according to the present invention may be combined with a known KLH solution (Calbiotec, 50% glycerol dissolving 125 mg per 1 ml of solution) as a carrier protein to enhance antigenicity.
- Diluents used in the compositions according to the invention may be selected based on the method and route of administration and the actual standard drug composition.
- examples of diluents include water, saline, phosphate buffered saline and bicarbonate solutions.
- Adjuvants used in the compositions according to the invention are selected based on the method and route of administration and the actual standard drug composition.
- adjuvant include cholera toxin, dimeric enterotoxin of Escherichia coli (LT), liposomes and immune stimulatory complex (ISC0M).
- the route of administration may vary depending on the age, body weight, sex and general health of the subject with the risk of staphylococcal infection, but administration may be oral and parenteral (eg intravenous, arterial and topical). It can be administered by any of the routes. Especially, parenteral administration is preferable.
- Formulations for oral and parenteral administration and methods for their preparation are known to those skilled in the art.
- Formulations for oral administration and parenteral administration may be prepared by conventional procedures, for example, in combination with the aforementioned pharmaceutically acceptable carriers.
- Examples of formulations for oral administration include solids such as solvents, tablets, granules, powdered medicines or capsules. Or liquid formulations.
- Examples of formulations for parenteral administration include solvents, suspensions, ointments, creams, suppositories, eye drops and ear drops.
- biodegradable plymers e.g., ply-D, L-lactide-co-glycoside or polyglycoside
- buck base e.g., US patents
- 5,417,986, 4, 675, 381 and 4,450, 150 e.g., ply-D, L-lactide-co-glycoside or polyglycoside
- flavors and colorings may be added.
- Suitable pharmaceutical carriers, diluents and pharmaceutically necessary substances for their use are described in Remington's Pharmaceutical Sciences.
- the dosage of the composition according to the present invention is determined based on the type of adjuvant, the method and frequency of administration, and the desired effect and may generally be between 1 ig and 100 mg of WTA for single adult administration.
- the dosage may generally be from WTA-PGN l g to lmg in a single adult dose.
- the administration can be administered several times if necessary.
- the composition may be administered again by supplementing three times after the composition is initially administered at regular intervals.
- the compositions for the first and second reinforcement may be administered 8-12 weeks and 16-20 weeks after the first administration using the same formulation, respectively.
- the present invention also provides a method for preventing or treating a staphylococcal infection disease in a subject, comprising administering the above-described composition to a subject in need thereof.
- composition according to the present invention By administering the composition according to the present invention as described above it is possible to prevent or treat staphylococcal infection disease by simultaneously inducing oxokinetic action ( opS o ⁇ hagocytosi s) and phagocytosis (phagocytosi s).
- the method of the present invention increases the ⁇ ⁇ - ⁇ cell number, IL-17A production and IL- ⁇ production within 24 hours after administration of the composition in a subject.
- the methods of the present invention increase IL-10 production 12 hours after administration of the composition in the subject.
- the invention provides a soluble wall teicosic acid-attached method comprising the following steps: Provided are methods for preparing peptidoglycan (WTA-PGN):
- step (5) obtaining soluble WTA-PGNol from the enzyme treatment of step (5).
- WTA-PGN soluble wall teicosic acid-attached peptidoglycan
- step (1) obtains a double mutant strain from the wild type Staphylococcus aureus / / (lipoprotein diacylglycerol transferase) and oatA (0 ⁇ acety ⁇ transferase) gene deletion.
- the double mutant strain (/ g oatA), which lacks the / ⁇ (lipoprotein diacylglycerol transferase) and os O-acetyl transferase genes obtained in step (1), has no possibility of lipoprotein contamination due to the deletion of the lgt gene. Pure WTA-PGN can be easily obtained, and the double mutant strain used in step 1 has no acetyl group at MurNAc residue of PGN due to deletion of oat A gene. It can be readily degraded by pins or ⁇ -lytic enzymes.
- Such double mutant strains may be obtained by conventional mutation methods known from wild-type staphylococci, for example methicillin-resistant staphylococci (MRSA), methicillin-sensitive staphylococcus (MSSA) or pathogenic staphylococci.
- MRSA methicillin-resistant staphylococci
- MSSA methicillin-sensitive staphylococcus
- pathogenic staphylococci for example, the double mutant strain is resistant to phleomycin. Resistant to erythromycin and the T363 strain (Lakayama M et al., Journal of Immunology 189: 5903-591, 2012), which lacks the lipoprotein di cylglycerol transferase (IGT) gene.
- ITT lipoprotein di cylglycerol transferase
- 0-acetyl transferase (0-acetyl transferase, T0003 strain lacking the oat gene (Park KH et al., Journal of Biological Chemistry 285, 27167-27175, 2010) was prepared by transducing via phage 80
- step (2) the double mutant strain is disrupted and an insoluble WTA-PGN is obtained from the resulting lysate.
- Step (2) is described by Park KH et al., Journal of Biological Chemistry 285.
- step (2) may comprise culturing the double mutant strain obtained in step (1), crushing cells, and obtaining insoluble WTA-PGN therefrom.
- step (3) the insoluble WTA-PGN is treated with ⁇ -lytic enzyme.
- the ⁇ -lytic enzyme plays a role in degrading pentaglycine ((Gly) 5 ) linkages linking the stem peptides present at the MurNAc residue of the insoluble FTA-PGN obtained in step (2) to insoluble WTA-PGNol soluble WTA. Change to PGN.
- Such ⁇ -lytic enzymes are commercially available or described in Li et al. It can be isolated and purified according to the methods described in Journal of Biochemitry 122, 772-778, 199. Examples of commercially available ⁇ -lytic enzymes include, but are not limited to, lysostaphin.
- Step (3) may be carried out by suspending the insoluble WTA-PGN obtained in step (2) in a buffer and then adding ⁇ -lytic enzyme and reacting at 30 to 40 ° C. for 10 to 14 hours with stirring.
- step (4) a soluble WTA-PGN containing fraction is obtained from the enzyme treatment of step (3).
- the ⁇ -lytic enzyme treatment is passed through HPLC to obtain a fraction, and then the fraction containing soluble WTA-PGN is selected from the fraction.
- the soluble WTA-PGN containing fractions can be obtained by passing the enzyme treatment of step (3) through high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- the fraction containing WTA-PGN in the fractions passed through the HPLC can be identified by PAGE or silver nitric acid stain.
- the column used in the HPLC purification may include Hi Tr ap-Q (GE Heal thcare), which is an anion exchange resin that binds to the anion of WTA's revitalized phosphate, but is not limited thereto.
- Hi Tr ap-Q GE Heal thcare
- the soluble WTA-PGN containing fractions are treated with lysozyme or mutanolysin.
- the lysozyme or mutanolysine used above converts the polymeric PGN to an oligomeric PGN by breaking down the bond between MurNAc and Gl cNAc of PGN in WTA-PGN.
- Step (5) may be carried out by suspending the soluble WTA-PGN obtained in step (3) in a complete solution, and then adding lysozyme or mutanolysine and reacting with stirring at 30 to 4C for 10 to 14 hours.
- step (6) soluble WTA-PGN is obtained from the enzyme treatment of step (5).
- the soluble WTA-PGN can be obtained by passing the enzyme treatment of step (5) through high performance liquid chromatography (HPLC).
- a lysozyme or mutanolysine enzyme treatment is passed through HPLC to obtain a fraction, and then the fraction containing soluble WTA-PGN is selected from the fraction.
- the selection of the fractions can be performed based on the amount of IL-17A produced after injection of each fraction into the mouse abdominal cavity.
- the column used in the HPLC purification may include HiTrap-Q (GE Heal thcare), but is not limited thereto.
- the method for preparing soluble wall teichoic acid-attached peptidoglycan (WTA-PGN) according to the present invention may further comprise the step of further purifying the WTA-PGN after step (6).
- WTA-PGN Further purification of the WTA-PGN can be performed by gel filtration chromatography or reverse phase liquid chromatography.
- the soluble WTA-PGN prepared in step (6) is subjected to gel filtration chromatography with Sephacryl S-200 HR columnol or reversed phase liquid chromatography with Symmetry Shiel d TM RP18 column. Can be further purified.
- the soluble WTA-PGN prepared in step (6) was subjected to gel filtration chromatography using Sephacryl S-200 HR column and reverse phase liquid chromatography using two Symmetry Shiel TM RP18 columns. After further purification.
- lipoprotein diacylglycerol t ransferase is lipoprotein diacylglycerol transferase.
- Defective T363 strain (Nakayama M et al., Journal of Immunology 189: 5903-591, 2012) and 0-acetyl transferase (oat A) gene resistant to erythromycin 5.
- Aureus T384 strain was prepared by transducing the T0003 strain (Park KH et al., Journal of Biological Chemistry 285, 27167-27175, 2010) via phage 80.
- the strain can be used to isolate WTA-PGN and PGN without lipoprotein contamination due to the deficiency of the lgt gene, as well as the isolated PGN due to the lack of the oatA gene because there is no acetyl group in the PGN MurNac residue 6 position oxygen. It can be easily disassembled.
- Example 2 Isolation and Purification of Soluble WTA-PGN Insoluble WTA-PGN was obtained from the gtl AoatA variant strain prepared in Example 1, after which soluble WTAol was isolated and purified (see FIG. 2).
- Insoluble WTA-PGN is described by Park KH et al. , Journal of Biological Chemistry 285, 27167-27175, 2010; Jung D J et al. , Journal of I'un logy 2012, 189: 4951-4959, 2012] was isolated and purified.
- Dispense 6 stainless steel disruption bottles The crush bottles were washed with 20 mM citrate complete solution (pH 4/7) with lMNaCl added to reach a total volume of 20 ml for each bottle. In order to prevent overheating, the crush bottle was kept on ice, and the bacteria were crushed for 2 minutes with a bead beater, and the process of keeping the ice for 2 minutes was repeated 7 times. The crushed bacteria were transferred to a new 50 ml tube and centrifuged at 3,000 rpm for 4 minutes at 4 ° C. for 15 minutes. The supernatant was then transferred to a 50 ml conical tube and centrifuged at 15,000 rpm, 4 ° C for 10 minutes using a high-speed centrifuge.
- the pellet is suspended in 10 ml of 20 mM citrate complete solution (pH 4.7), then 10 ml of 20 mM citrate buffer (pH 4.7) containing 1% sodium dodecyl sulfate (SDS) is added to bring the final SDS concentration to 0.5%. Fit.
- SDS sodium dodecyl sulfate
- the supernatant was removed by centrifugation at rpm, 20 ° C for 5 minutes.
- the pellet was washed twice with 30 ml of 20 mM citrate buffer (pH 4.7) containing 1 M NaCl, and the pellet was suspended with water for injection warmed to 30 ° C for complete removal of the remaining SDS at 15,000 rpm, 20 ° C. Centrifuge for 5 minutes. When the water for injection into the pellet was shaken, the washing was repeated until no foam came out, and the pellet without the foam was suspended in 10 ml of water for injection and stored at room temperature for 10 minutes.
- the concentrated sample was subjected to size exclusion chromatography on a Sephacryl S-100 column (1.6 cm X 87 cm) with 10 mM sodium citrate complete solution containing 200 mM NaCl (pH 6.0).
- the absorbance of the filtrate was measured at 280 nm, and the filtrates were concentrated by collecting the compartments showing the increased compartment absorbing activity. Based on the results of (1997), the ⁇ -lytic enzyme compartment was selected.
- size exclusion chromatography was carried out in Superdex -75 (1 cm X 30 cm) with 10 mM sodium citrate (pH 6.0) containing 200 mM NaCl to obtain -lytic enzyme.
- the obtained ⁇ -lytic enzyme was confirmed lytic activity or lytic activity in the culture of PLO suspension and column fractions derived from microlocus luteus (ATCC 9341) or insoluble staphylococcus aureus, Procise® Protein sequencer (Cat. # 491- 0, Applied Biosystems, Stafford, TX, USA), the N-terminal sequence was analyzed by SPNGLLQFPF. The N-terminal sequence was analyzed by SPNGLLQFPF, and the result of electrophoresis was found to be a single band having a molecular weight of about 25 kDa. It was identified as a -lytic enzyme.
- Tris-HCKpH 7.0 Tris-HCKpH 7.0
- insoluble WTA—PGN was added with 350 ⁇ -lytic enzyme 350 quantified by Bradford method per 100 mg and reacted for 12 hours in a stirred incubator at 37 ° C, 180 rpm.
- the reaction solution was deactivated by placing the reaction solution in a 60 ° C constant temperature water bath for 10 minutes, the supernatant was obtained by centrifugation at 15,000 rpm, 4 ° C for 10 minutes.
- lyophilized soluble WTA-PGN 100 mg was dissolved in 10 ml of 20 mM Tris-HCKpH 7.0) and lysozyme (Cat. # 62970, Sigma-Aldr ich Co. LLC., Saint Louis, MO USA) was added 1.25 mg. After reaction at 37 ° C, 180 rpm for 12 hours in a stirred incubator. After the reaction solution was deactivated by leaving the reaction solution in a 60 ° C constant temperature water bath for 10 minutes, the supernatant was obtained by centrifugation at 15,000 rpm, 4 ° C for 10 minutes.
- a Sephacryl S-200 HR column was used.
- the HPLC apparatus (805 MANOMETRIC MODULE, 811C DYNAMIC MIXER, 305 PUMP, 306 PUMP, 151 UV / VIS Detector, Gi l son, USA) used the product of Gi lson, Sephacryl S-200 HR, 25 ⁇ -75 ym (Cat. # 17-0584 ⁇ 01 , GE Healthcare Li Sciences, England) columns were used by GE Healthcare Li Sciences.
- Soluble WTA-PGN (53.5 mg), previously isolated, was dissolved in 400 ⁇ l of distilled water and injected into an HPLC injector.
- the HPLC apparatus (805 MANOMETRIC MODULE, 811C DYNAMIC MIXER, 305 PUMP, 306 PUMP, 151 UV / VIS Detector, Gi lson, USA) used a product of Gi lson, Symmetry Shield TM RP18 (5 um, 4.6x250 mm) column (Cat 186000112, Waters, Ireland) used Waters, MF TM Membrane Filters 0.45 ura (Cat JHAWP04700, Merck, Germany) used Merck products. In addition, Speed Vac (Cat. # CVE-100, EYELA, Japan), Evaporator (Cat. # CCA-1110, EYELA, Japan), and lyophilizer (Cat.
- insoluble WTA—PGN was suspended in 19 ml of 20 mM citrate complete solution (pH 4.5), followed by 1 ml of trichloroacetic acid (100 mg / ral) to a final concentration of 5 mg / ml. To be.
- the suspension was reacted in a stirred incubator at 3 (C, 180 rpm for 12 hours and then centrifuged for 10 minutes at 10,000 rpm and 4 ° C.
- the supernatant was transferred to a 50 ml tube and subjected to acetone precipitation for 1 hour, then 15,000 rpm , Centrifuged for 25 min at 4 ° C. Transfer the pellet to a 1.5 ml microcentrifuge tube to acetone. It was removed and suspended in 1 ml of 20 mM Tris-HCKpH 7.0) buffer.
- HPLC HPLC was performed using a Hitrap-Q column. All lines and columns were washed with A complete solution of 20 mM Tris-HCl (pH 7.0), and the sensitivity of the UV detector was set to 1 and the absorbance was set to 220 nm.
- the sample to be loaded was filtered through a 0.45 um filter and then loaded.
- the flow rate was set at 0.5 ml / min to allow the sample to bind to the Hitrap-Q column, and the impurities were removed by washing the Hitrap-Q column while maintaining the existing flow rate until equilibrium.
- WTA was removed by TCA to obtain PGN from lyophilized insoluble WTA-PGN.
- TCA-treated insoluble FTA-PGN was resuspended in 19 ml '20 mM citrate complete solution (pH 4.5) to obtain WTA and 1 ml trichloroacetic acid (100 mg / ml) added to a final concentration of 5 mg / ml. It was made to be. 30 ° C, stirred at 180 rpm After reacting for 12 hours in the incubator, it was centrifuged for 10 minutes at 10,000 rpm, 4 ° C.
- the pellet was suspended in 30 ml of sterile distilled water, centrifuged at 10, 000 rpm, 4 ° C for 10 minutes and washed five times to remove TCA completely. It was suspended in 15 ml of water for injection and then lyophilized to obtain insoluble PGN.
- ⁇ 4-2> Treatment of ⁇ -lytic enzyme to purify soluble PGN into soluble PGN 100 mg of lyophilized insoluble PGN was suspended in 10 ml of 20 mM Tri s-HCKpH 7.0 to a concentration of 10 mg / ml. After centrifugation at 15,000 rpm, 4 ° C. for 10 minutes, and washed three times with 20 ml 20 mM Tri s-HCKpH 7.0). The washed insoluble PGN was suspended in 20 ml of 20 mM Tri s-HCKpH 7.0) and purified per OO mg of insoluble PGN — 350 lytic enzyme 350, pH 7.0, and stirred at 37 ° C, 180 rpm. Reaction for hours.
- a gradient was set for 30 minutes from 0> to 100% with water for injection containing 1 M NaCl, a B complete layer.
- the elution results are shown in FIG. 7.
- the pass-through solution (A fraction) was assumed to be a fraction containing soluble PGN from which WTA was removed, and the fraction eluted by B complete solution containing 1M NaCl (B fraction) was not removed. Since it was estimated to be WTA-PGN or WTA, only A fraction was collected and lyophilized.
- the lyophilisate was dissolved in water for injection at a concentration of 20 mg / ml, and then injected into a Toyopear l HW 55 S (Cat. # 14686, TOSSO Bioscience, Japan) column to perform gel filtration.
- Gel filtration conditions were equilibrated with water for injection, flow rate 0.5 / min, absorbance 215 nm, sensitivity 1, operating time was 50 minutes.
- the elution pattern by the gel filtration is shown in FIG. As shown in FIG. 8, two peaks were observed upon gel filtration.
- Example 4 Characterization of Biochemical Properties of WTA-PGN and WTA Isolation and Purification of Biochemical Properties of Purified WTA-PGN and WTA, 27% PAGE and silver nitrate staining were performed. Analysis by chromatography and the amount of phosphate and GlcNAc residues present in WTA was quantified by known assay methods.
- the experimental animals were purchased at 5 weeks of age from 15 ⁇ 0.5 g of specific pathogen-free (57) SPF (specific pathogen-free) C57BL / 6J female mice from the Biomedical Mouse Center of the Korea Research Institute of Bioscience and Biotechnology (Ochang Campus, Chungcheongbuk-do, Korea). Animal laboratory environment (Cat. # AAAC2051, ⁇ Jeiotech, Gene Deletion rea) for 1 week while feeding commercial solid feed (Cat. # 5L79, Orient Bio, Gene Deletion rea); 20-25 ° C, 55% humidity).
- SPF specific pathogen-free
- the diet was completely divided into each group by the randomized design, and 6-12 animals in each group and 6 animals in each group were provided in the feeding cages to provide diet and drinking water by the ad libitum.
- the weight and dietary intake of each experimental animal were measured once daily, and the lighting was turned on and off every 12 hours.
- MRSA to be used for in vivo infection studies. aureus USA30Q strain) and MSSA (5. aureus NRS184 strain) preparation
- the amount of IL-17A was measured.
- MRSA ⁇ . aureus USA300 strain 1 ⁇ 10 8 CFU / 100 ⁇ 1 PBS was injected by ip injection. Mice in the control group were used by ip injection of 100 ⁇ l of PBS, and naive mice were used as the control group. Mice were regenerated at 0, 3, 6, 9, 12, 24, 48 and 72 hours after bacterial challenge to assess systemic infection levels and immune response.
- MRSA S. aureus USA300 strain
- MSSA 5. aureus RS184 strain
- Mouse abdominal leachate was in 2 ml PBSCCat. # 17-516Q, BioWhittaker®, LONZA, USA), followed by centrifugation at 2,000 rpm for 10 minutes to store the supernatant at -80 ° C for analysis of cytokines using ELISA.
- Resuspend in 1640 medium cRPMI; RPMI 1640: Gibco®; 10% FBS: Gibco®; 100 mM L-glutamine: Gibco®; and 100 mg / ml penicillin / Streptomycin: Gibco®).
- Erythrocytes were lysed using RBC lysate complete solution (Cat. # 420301, Bio legend, San Diego, Calif., USA) for red blood cell removal and cells were resuspended again with cRPMI.
- IL-17A, IL-23, IL- ⁇ , IL-10 and IFNy are available from R &D's Duoset® ELISA kit (R & D Systems Inc., Minneapolis, USA, USA) and ELISA Ready-SET-Go!
- the kit (eBioscience, San Diego, Calif., USA) was used to measure the supernatant of the intraperitoneal leachate. ELISA kit information for each cytokine is shown below.
- the microplate reader Cat. # 51119000, Thermo Fisher Scientific Inc., The absorbance values measured at 450 nm using Waltham, MA, USA) were corrected to 550 nm values.
- PECs from mice immunized with Naive mice and WTA derivatives were isolated as described above and transferred to PE-96 platelets (2-3X10 5 cells / well) in a 1.5-well cRPMI medium to attach macrophages and dendritic cells. Incubated under 37 ° C., 5% CO 2 conditions (Cat. # MC0-17A, SANYO, Japan) for hours. The medium was then aspirated off and replaced with RPMI without antibiotics.
- Macrophages and dendritic cells were cultured using murine and Pan T cell isolation kit II (Cat. # 130-095-130, Miltenyi Biotec, Bergisch Gladbach, Germany).
- Pan T cell isolation kit II Cat. # 130-095-130, Miltenyi Biotec, Bergisch Gladbach, Germany.
- ⁇ ⁇ ⁇ cells were subjected to FACS isolation using ⁇ ⁇ TCR specific Abs as follows.
- Stained cells were pressurized through isometric bottom tubes (Cat. # 352235, Tewksbury, MA, USA) with cell strainer snap caps and flow cytometry (MoFlo® Astrios TM cell sorter, Beckman Coulter, Inc., South Kraemer Boulevard Brea) , CA, USA). Purity of the isolated cells was greater than 95%.
- RNA isolation was performed according to the manufacturer's protocol, and mRNA was synthesized for cDNA synthesis using oligo (dT) primers (Cat. 1101, Pr omega Corpor at i on, Madison, WI, USA) and Improm-II system (Cat. # A3800). , Pr omega Corporation, Madison, Wis., USA), reverse transcription into cDNA on an RT—PCR instrument (C1000 Touch TM Thermal Cycler, Bio-Rad, Hercules, Calif., USA) at a volume of 20 ⁇ 1. Transcribed cDNA was amplified using a qRT-PCR instrument (Cat.
- CD121a (IL-lRa) PE Bio legend JAMA- 147
- TLR3 F 5 '-TAA AGC GAG TTT CAC ITT CAG G-3' (SEQ ID NO: 21)
- the experimental animals were purchased from Orient Bio (Gyeonggi-do, South Korea) with a NZW rabbit (Yac; NZW (KBL), female) weighing 2 ⁇ 0.1 kg in weight, and commercially available solid feed before starting the experiment : ⁇ . # 38302- ⁇ , 0 ⁇ ⁇ 1 ⁇ 1 1 ⁇ 113 , Inc. Feeding the gene-deficient rea, it was adapted to the animal laboratory environment (rabbit cage (Cat. # DJ117, Daejong Machinery Industry, South Korea); 20-25 ° C, 55% humidity) for 1 week. One experimental animal was placed in a breeding cage to provide diet and drinking water by free feeding. The weight and dietary intake of each experimental animal were measured once daily and the lights were turned on and off at 12 hour intervals.
- Zoletil® 50 (Bakbark Korea, Korea) and Xylazine hydrochloride (Cat. # 1251, Sigma ⁇ Aldrich Co. LLC., Saint Louis, M0, USA) for animal anesthesia are 30 mg each. /0.6 ml / 2 kg and 9.328 mg / 0.4 ml / 2 kg Mix in concentration and inject with im.
- the animals were purchased from Orient Bio Co., Ltd. (Crl0ri; HA, Female) with a weight of 250 ⁇ 10 g. 1 week animal lab environment (Cat. # AAAC2051, Jeiotech, South Korea) while feeding commercial solid feed (Cat. # 5026, Orient Bio, Korea); 20 ⁇ 25 ° C, humidity 55%).
- One experimental animal was placed in a breeding cage to provide diet and drinking water by free feeding. The weight and dietary intake of each experimental animal were measured once daily, and the lighting was turned on and off every 12 hours.
- zoletil ® 50 (Burke Korea, Gene Deletion Rea) and xylazine hydrochloride (Cat. # 1251, Sigraa-Aldrich Co. LLC., Saint Louis, M0 USA)
- the mixture was injected into im with 3 mg / 0.06 ml / 100 g and 0.9328 mg / 0.04 ml / 100 g, respectively.
- the shaved area was divided in half (horizontal (3 cm) x vertical (6 cm)) and sectioned, PBS (100 ⁇ ) as a control on the left side and WTA-PGN (20 ug / 100 ⁇ ) on the right side were immunized with id. .
- Intradermal immunization and MRSA (USA300) infections of 0 WTA, PGN, and WTA-PGN derivatives were performed on days 0, 14, 28, 42, and 56, respectively, in PBS (Cat. # R7-516Q, Lonza Walkersville, Inc.). , MD, USA) and 20 WTA, PGN derivatives were immunized a total of 5 times by id injection of 50 ⁇ l, 7, 21, 35, 49, 63, 7 days before the start of immunization and 7 days after each immunization.
- Kidney tissues with abscess formation were observed as a solution containing 10 ml of 10 mM EDTA (Ethylenediarainetetra acetic acid; Cat # .EDT001.500, Bioshop, Canada) and 0.9% NaCl (Cat. # 14002, Sino Pharmaceutical, Korea). After homogenization, the homogenates were serially diluted and spread 50 ⁇ l in sheep blood agar plates (Cat. # AM601-01, Asan Pharmaceutical Co., Ltd., gene deletion rea), followed by 37 ° C. incubator (Cat. # SB_9, EYELA, Japan) and the number of colonies after counting for 24 hours.
- 10 mM EDTA Ethylenediarainetetra acetic acid
- Cat. # 14002 Sino Pharmaceutical, Korea
- H & E Hematoxylin-eosifi
- the collected tissue was subjected to a 10% formalin solution (Cat. # HT501128, Sigma-Aldr ich Co.
- Example 6 ⁇ ⁇ T Cell Mediation in Human Body by Purified WTA-PGN Derivatives Protective effect against IL-17A secretion and MRSA infection
- the purified purified WTA-PGN derivatives were prepared at different concentrations (0, 50, 100, 200 ug / 100 ⁇ 1 in PBS).
- the results of observing IL-17A and IL- ⁇ production in the abdominal cavity according to the present invention are shown in FIGS. 11A and 11B, respectively.
- the time dynamics for cytokine expression such as IL-17A and IL- ⁇ were observed by ELISA.
- IL-17A was induced at 6 hours after increasing expression from 3 hours after WTA-PGN injection, and then decreased rapidly after 24 hours, and was not expressed at 24 hours, and all time periods when injection of the same amount of the combination of WTA and PGN were injected.
- IL- ⁇ expression was also highest at 3-6 hours after WTA-PGN derivative injection and decreased to control level at 24 hours.
- the WTA and PGN complex showed the maximum IL-I ⁇ expression at 3 hours, but rapidly decreased at 6 hours.
- the expression level of IL-1 ⁇ was found to increase in concentration-dependent manner as in IL-17A (FIG. 11B).
- Thl7 cells T cells capable of producing IL-17A in the body are known as Thl7 cells.However, if IL-17A is continuously secreted by Thl7 cells, the neutrophils may be excessively collected at specific sites or in host tissues. Since it has been reported to cause autoimmune diseases such as lupus and rheumatoid arthritis by destroying organs, it has been suggested that the inflammation that induces Thl7 cell mediated IL-17A expression is not useful as a useful vaccine or immunomodulator.
- IL-17A production increased from 3 hours after injection of WTA-PGN derivatives, peaked at 6 hours, decreased after 9 hours, and was not produced at 12 hours.
- IL- ⁇ was similar to the expression pattern of IL-17A. It showed a tendency, but after peaking at 6 hours, it began to decrease, and maintained at a relatively high level until 12 hours, but was not expressed after 24 hours.
- IL-10 production gradually increased from 3 hours to maximum at 12 hours, decreased from 24 hours, but remained high until 48 hours, but rapidly decreased from thereafter to almost no production after 72 hours. Did you know that it's a weird thing
- IL-17A derived from ⁇ ⁇ was produced by the WTA-PGN derivative.
- Fig. 13 shows the results of experiments demonstrating that IL-17A generated at the time of WTA-PGN injection is IL-17A derived from ⁇ ⁇ ⁇ cells using flow cytometry. After WTA-PGN injection, cells intraperitoneally were collected over time, and only CD3 + T cells were collected first, then ⁇ cells with ⁇ ⁇ ⁇ cell receptor ⁇ T cel l receptor ( ⁇ ⁇ TCR) were collected to determine the percentage of these total ⁇ cells.
- WTA-PGN is a novel immune modulator (i ⁇ une modulator) capable of inducing selective ⁇ ⁇ ⁇ cell mediated IL-17A expression.
- IL-17A production from CD4 + and CD8 + T cells was not observed. This fact suggests that WTA-PGN derivatives are not involved in adaptive immune responses derived from CD4 + and CD8 + T cells, and produce only IL-17A from ⁇ ⁇ ⁇ cells to regulate cellular immune response by neutrophils. new It was found to be an immunomodulatory substance.
- WTA derivatives produced ⁇ ⁇ ⁇ cell-derived IL-17A, resulting in VY 2/4 _ / lacking the VY 2/4 gene, a major subset of ⁇ ⁇ TCR, using WTA using mice and wild-type mice (wi ld-type).
- IL-17A and IL- ⁇ were expressed as expected in the wild-type mouse group injected with WTA-PGN, as shown in FIGS. 15A and 15B, whereas the VY 2/4 — / _ mouse group did not produce such cytokines.
- WTA-PGN is the main subgroup of TCR.
- mice were pretreated with WTA-PGN, WTA and PGN derivatives. Investigation of changes in inflammatory and anti-inflammatory cytokines by re-infection showed that IL-17A production was expressed at 6 hours after infection with the USA300 strain, and then decreased to levels similar to controls at 24 hours (Figure 16A). .
- IL-17A was expressed in mice pretreated with WTA and PGN three times, but its expression was about half that of WTA-PGN, and the specificity was that IL-17A was expressed after three times pretreatment. It can be seen that the amount is about 10 times higher expression.
- IL- ⁇ ⁇ production was highest at 6 hours after USA300 infection, and significantly decreased at 24 hours.
- the expression of IL- ⁇ ⁇ in WTA and PGN pretreatment groups was nearly identical to that of WTA-PGN at 6 hours. This fact indicates that IL- ⁇ ⁇ production was similar to that of WTA-PGN by re-infection of USA300 strain in mice pretreated with ⁇ 'PGN 3 (Fig. 16B).
- IL-23 production was interestingly expressed only in the WTA-PGN group at 6 hours after reinfection of the USA300 strain, but not at 24 hours later. These results can be expected that IL-23 production is closely related to memory ⁇ ⁇ ⁇ cell mediated IL-17A production (FIG. 16C).
- IFN Y after infection with the USA300 strain, showed maximum expression at 6 hours in mice pretreated with WTA and PGN, and significantly decreased at 24 hours thereafter.
- IFN Y expression in mice pretreated with WTA-PGN showed the lowest expression in WTA-PGN group, as opposed to IL-17A expression.
- IL-10 an anti-inflammatory cytokine
- the expression of IL-10 increased to 3 hours after infection with the USA300 strain, and slightly decreased to 12 hours, but decreased to 48 and 72 hours after peaking again at 24 hours.
- the production of IL-10 was maximal at 24 hours when the expression of the inflammatory cytokines IL-17A, IL- ⁇ ⁇ and IL-23 was completely inhibited. It can be seen that IL-10 effectively inhibits the expression of IL-17A (FIG. 16E).
- mice pretreated with LP WTA-PGN 3 generated memorable ⁇ ⁇ T cells with a CD44 high / CD27 100 W marker.
- ⁇ ⁇ T cells of mice pretreated with WTA-PGN were collected 3 hours after USA300 infection, and the expression of CD44 high / CD27 l0W ⁇ ⁇ ⁇ cells, markers of memory ⁇ ⁇ ⁇ cells, was examined.
- the expression of IL-17A was higher than that of the control group, whereas IL-17A expression was not observed in CD27 + ⁇ ⁇ ⁇ cells (Figs. 17A and ⁇ 7 ⁇ ).
- Vy4 + cells were reported to be more and more involved in the successive 5. aureus infections and memory reactions, and to be directly involved in the production of IL-17A. 3) ALI I unol 2014; 192: 3697 -3708). vi) IL-23 expression in dendritic cells
- mice were immunized three times with abdominal cavity (i.p) with WTA-PGN and then infected with USA300 strains of 1 ⁇ 10 8 cells on day 35 and observed organ formation and abscess formation in the abdominal cavity 72 hours later. It was. The results are shown in FIG.
- mice immunized with WTA-PGN could effectively protect the living body even at high concentrations of MRSA infection caused by early cellular and memory immune responses.
- WTA-PGN which protects against MRSA infection
- NZW rabbits and guinea pig models were immunized subcutaneously with WTA-PGN (20 ⁇ xg WTA-PGN / 100 ⁇ 1 PBS), and 6 hours later, MRSA (USA300 of 5X10 8 CFU) was injected subcutaneously for protection. was observed.
- the size of the abscess was significantly smaller in the animals immunized with WTA-PGN (20 ug WTA-PGN / 100 ⁇ 1 PBS) compared to the control group immunized with PBSU00 ⁇ ) in both NZW rabbits and guinea pigs. And it can be observed that the rapture quickly (Figs. 26A and 26B). This confirms the fact that WTA-PGN is responsible for MRSA infections in the guinea pig, which is believed to have the most similar immune system to NZW rabbits and humans. Proved effective protection.
- Wild-type, TLR-9-gene and Caspase-1-gene-deficient mice were injected with WTA-PGN isolated from l oa ⁇ l / and WTA-PGN isolated from wild type bacteria, and 6 hours later in intraperitoneal leachate.
- IL-17A production was measured in IL-17A and IL- ⁇ expression only in wild-type mice injected with WTA-PGN isolated from Zl o ⁇ zl /, whereas TLR-9-gene deletion, Caspase- It was shown that these cytokines are not produced in 1-gene deficient mice (FIGS. 28A and 28B).
- Macrophages, dendritic cells and ⁇ ⁇ ⁇ cells were isolated from mouse peritoneal leaching cells (PEC) to understand the higher signaling pathways required for ⁇ ⁇ ⁇ cell-dependent IL-17A secretion and the biological function and mechanism of WTA-PGN. Cytokines derived from cells were examined (FIG. 29).
- IL-17A was in ⁇ ⁇ ⁇ cells
- IL- ⁇ was in dendritic cells and ⁇ ⁇ ⁇ cells
- IL-12 p40 (IL-23) was in dendritic cells
- IFN Y was ⁇ . It was revealed that each is expressed in ⁇ T cells.
- IL-23 and IL- ⁇ expression in dendritic cells plays an important role in the production of IL-17A in non-classical ⁇ cells, ie ⁇ ⁇ ⁇ cells, WTA-PGN It was deemed necessary to study more specifically how these cytokines recognize ligands and interact with each other during immunization.
- wild-type and NLRP3-gene deficient mice were used to immunize WTA-PGN, isolate macrophages, dendritic cells, and ⁇ ⁇ T cells, and express the gene expression status up to NLRP3, cytokines and TLR1 9 in qRT-PCR.
- NLRP3 was produced mainly in dendritic cells and ⁇ ⁇ T cells, and was higher in the control group treated with nothing in wild-type mice.
- Wild-type mouse group showed higher expression than NLRP3 gene deficient mouse group (FIG. 30).
- NLRP3 is expressed in dendritic and intracellular inflamasomes
- the expression of IL- ⁇ was high in both dendritic cells and ⁇ ⁇ T cells, and the NLRP3 gene expression in NLRP3-gene-deficient mice in this experiment was shown to affect dendritic cells and ⁇ ⁇ ⁇ . It was thought that the same plaques of NLRP3 could also be present in ⁇ ⁇ ⁇ cells, which appeared almost identically in cells, suggesting a new fact that has not been reported so far (FIG. 30A).
- IL-17A The expression of IL-17A was not expressed at all in the control group, whereas, when immunized with WTA-PGN, the expression level increased only in ⁇ ⁇ ⁇ cells obtained from the wild-type mouse group and the NLRP3 gene-deficient mouse group. It was higher than the expression level in the NLRP3-gene deficient mouse group. This is presumed to be the result of decreased expression of IL-17A in NLRP3—gene deficient mice, in which the IL-I ⁇ production is inhibited in the inflamasome of dendritic cells, which does not stimulate ⁇ cells (FIG. 30B).
- IL-23 is a heterodimer form consisting of IL-12p40 and IL-23pl9.
- IL-12p40 was found in dendritic cells of wild-type and NLRP3 gene-deficient mice immunized with WTA-PGN. Highly expressed in macrophages and dendritic cells of the gene-deficient mouse, but the expression is insignificant compared to IL-12p40 (Fig. 30C & 30D).
- IL- ⁇ was not expressed at all in the control group, but when immunized with WTA-PGN, dendritic cells> ⁇ ⁇ ⁇ cells> macrophages in the wild-type mouse group, and ⁇ ⁇ ⁇ cells in the NLRP3-gene deficient mice. > Macrophages (Fig. 30E), IFN Y expression was significantly suppressed in wild-type mouse group immunized with WTA-PGN and high in ⁇ ⁇ ⁇ cells of control and NLRP3 gene deficient mouse groups ( Figure 30F).
- Anti-WTA-IgG was generated upon subcutaneous immunization of WTA and WTA-PGN in the mouse model.
- the control group injected with PBS lost more than 15% of body weight on the 2nd day after infection, and continued to maintain low weight, while the WTA and PGN groups had lower weight loss than the PBS group, and the WTA-PGN group had about 5% weight loss. After losing weight, he returned to his original weight six days after bacterial infection.
- WTA, PGN, and WTA-PGN derivatives isolated from staphylococcal cell walls were immunized with subcutaneous injection in mice. On the 70th day, USA300 strains were injected intravenously and infected. The results of investigating whether the strain forms CFU and abscess are shown in FIGS. 34A and 34B.
- Necrosis of glomeruli in the cortex and immune cell leaching and abscesses including polymorphonuclear leukocytes, macrophages and lymphocytes were identified in the medulla.
- the medulla In the cortex, In the mice immunized with WTA-PGN, the ' morphology of glomerular sac similar to the mouse control group was maintained, but the necrosis of glomerular sac was found in the mice immunized with PBS and PGN.
- a few immune cell leachates were found in the mice immunized with WTA-PGN and showed a similar pattern to the control mice. Abscess was not found at all, showing a pattern close to normal tissue.
- the PBS group and the PGN group large abscesses were found, and in the cortex medulla, kidney damage was the lowest in the order of WTA-PGN>WTA>PGN> PBS group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020167034875A KR20170005852A (ko) | 2014-05-29 | 2015-05-29 | 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
US15/314,324 US20170189473A1 (en) | 2014-05-29 | 2015-05-29 | Composition for preventing or treating staphylococcus aureus infection |
CN201580028333.8A CN106413737A (zh) | 2014-05-29 | 2015-05-29 | 用于预防或治疗金黄色葡萄球菌感染的组合物 |
JP2017515649A JP2017518373A (ja) | 2014-05-29 | 2015-05-29 | スタフィロコッカス・アウレウス感染疾患の予防または治療用組成物 |
EP15800382.2A EP3150217A1 (en) | 2014-05-29 | 2015-05-29 | Composition for preventing or treating staphylococcus aureus infection |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462004564P | 2014-05-29 | 2014-05-29 | |
US62/004,564 | 2014-05-29 | ||
US201462040452P | 2014-08-22 | 2014-08-22 | |
US62/040,452 | 2014-08-22 | ||
US201462044196P | 2014-08-30 | 2014-08-30 | |
US62/044,196 | 2014-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015183041A1 true WO2015183041A1 (ko) | 2015-12-03 |
Family
ID=54699299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/005431 WO2015183041A1 (ko) | 2014-05-29 | 2015-05-29 | 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20170189473A1 (ko) |
EP (1) | EP3150217A1 (ko) |
JP (1) | JP2017518373A (ko) |
KR (1) | KR20170005852A (ko) |
CN (1) | CN106413737A (ko) |
WO (1) | WO2015183041A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749652A (zh) * | 2017-03-14 | 2017-05-31 | 天津喜诺生物医药有限公司 | 一种金黄色葡萄球菌肽聚糖的多克隆抗体 |
CN107596342B (zh) * | 2017-08-29 | 2021-08-31 | 苏州大学附属第一医院 | 产丙酮酸棒状杆菌肽聚糖、提取及抗感染应用 |
CN113425746A (zh) * | 2021-06-25 | 2021-09-24 | 楚东开 | 一种治疗化脓性骨髓炎的组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040247605A1 (en) * | 2002-12-02 | 2004-12-09 | Kokai-Kun John Fitzgerald | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
KR20100056510A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 유로딜라틴의 용도 |
KR101062525B1 (ko) * | 2002-11-12 | 2011-09-06 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 포도상구균 감염에 대한 다당류 백신 |
KR20110124060A (ko) * | 2010-05-10 | 2011-11-16 | 부산대학교 산학협력단 | Wta를 유효성분으로 함유하는 백신 조성물 |
WO2013168965A2 (ko) * | 2012-05-07 | 2013-11-14 | 목암생명공학연구소 | 포도상구균 감염 예방용 백신 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2525800B1 (en) * | 2010-01-19 | 2018-07-04 | Universitätsklinikum Freiburg | Enterococcal cell wall components and antibacterial use thereof |
-
2015
- 2015-05-29 EP EP15800382.2A patent/EP3150217A1/en not_active Withdrawn
- 2015-05-29 KR KR1020167034875A patent/KR20170005852A/ko unknown
- 2015-05-29 CN CN201580028333.8A patent/CN106413737A/zh active Pending
- 2015-05-29 JP JP2017515649A patent/JP2017518373A/ja not_active Withdrawn
- 2015-05-29 WO PCT/KR2015/005431 patent/WO2015183041A1/ko active Application Filing
- 2015-05-29 US US15/314,324 patent/US20170189473A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101062525B1 (ko) * | 2002-11-12 | 2011-09-06 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 포도상구균 감염에 대한 다당류 백신 |
US20040247605A1 (en) * | 2002-12-02 | 2004-12-09 | Kokai-Kun John Fitzgerald | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
KR20100056510A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 유로딜라틴의 용도 |
KR20110124060A (ko) * | 2010-05-10 | 2011-11-16 | 부산대학교 산학협력단 | Wta를 유효성분으로 함유하는 백신 조성물 |
WO2013168965A2 (ko) * | 2012-05-07 | 2013-11-14 | 목암생명공학연구소 | 포도상구균 감염 예방용 백신 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20170005852A (ko) | 2017-01-16 |
US20170189473A1 (en) | 2017-07-06 |
JP2017518373A (ja) | 2017-07-06 |
CN106413737A (zh) | 2017-02-15 |
EP3150217A1 (en) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McLoughlin et al. | IFN-γ regulated chemokine production determines the outcome of Staphylococcus aureus infection | |
Maisey et al. | Recent advances in understanding the molecular basis of group B Streptococcus virulence | |
CA2597263C (en) | Polypeptides from staphylococcus aureus and methods of use | |
JP5394233B2 (ja) | 自然免疫機構を活性化/抑制する作用を有する物質の評価方法及びスクリーニング方法、並びに、自然免疫機構を活性化/抑制するための薬剤、食品及びそれらの製造方法 | |
US8212007B2 (en) | Expression and purification of HIP/PAP and uses therefor | |
US20180237481A1 (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
Patel et al. | Immunological outcomes of antibody binding to glycans shared between microorganisms and mammals | |
KR20150024315A (ko) | 포도상구균 감염 예방용 백신 조성물 | |
WO2015183041A1 (ko) | 포도상구균 감염 질환의 예방 또는 치료용 조성물 | |
Schechter et al. | Host defenses to extracellular bacteria | |
JP2021000134A (ja) | 免疫低下状態の宿主のためのワクチン | |
Furuta et al. | CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog | |
Alshammari | Identification of more potent and efficacious analogs of the novel host-derived immunostimulant EP67 | |
Fong et al. | Reemergence of established pathogens in the 21st century | |
Jeannin | Introduction: historical background | |
Clarke | Role of CD4+ T cells in the regulation of the immune response against encapsulated Group B Streptococcus | |
AU2015258239B2 (en) | Polypeptides from staphylococcus aureus and methods of use | |
CN102448489B (zh) | 多肽和含有革兰氏阳性多肽的免疫组合物及使用方法 | |
de Jong | GENERAL DISCUSSION–Expanding the staphylococcal evasion repertoire | |
Fournier et al. | Staphylococcus aureus Recognition of | |
Bownik et al. | Influence of staphylococcal leukocidins on phagocyte and lymphocyte activity-a comparative study. | |
Seo | Investigation of lipoteichoic acid structure and function to establish its role in Gram-positive bacterial infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15800382 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017515649 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15314324 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20167034875 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015800382 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015800382 Country of ref document: EP |